Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.95 BRL | -10.11% | -1.00% | -40.72% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Its low valuation, with P/E ratio at 8.54 and 6.23 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company is in debt and has limited leeway for investment
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-40.72% | 341M | - | ||
-26.36% | 15.04B | B+ | ||
-1.80% | 11.9B | B | ||
+3.65% | 11.73B | B+ | ||
+8.83% | 10.68B | B+ | ||
+26.35% | 8.55B | B | ||
-8.21% | 7.35B | A- | ||
+9.84% | 6.48B | D | ||
+19.81% | 4.36B | B+ | ||
-4.42% | 4.28B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MATD3 Stock
- Ratings Hospital Mater Dei S.A.